Differential effect of HDAC3 on cytoplasmic and nuclear huntingtin aggregates

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Mano, Tatsuo ^a   Suzuki, Takayoshi ^b,c   Tsuji, Shoji ^a   Iwata, Atsushi ^a,c  

^a UNIVERSITY OF TOKYO   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE 3; HUNTINGTIN; PROTEASOME; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HTT PROTEIN, HUMAN; NERVE PROTEIN; PROTEIN AGGREGATE;

ARTICLE; BINDING AFFINITY; CELL FRACTIONATION; CELL VIABILITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUNTINGTON CHOREA; IMMUNOPRECIPITATION; PATHOGENESIS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN PURIFICATION; WESTERN BLOTTING; AMINO ACID SEQUENCE; CELL NUCLEUS; CHEMISTRY; CYTOPLASM; DRUG EFFECTS; ENZYME SPECIFICITY; EXON; GENETICS; HEK293 CELL LINE; HELA CELL LINE; METABOLISM; MOLECULAR GENETICS;

AMINO ACID SEQUENCE; CELL NUCLEUS; CYTOPLASM; EXONS; HEK293 CELLS; HELA CELLS; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; MOLECULAR SEQUENCE DATA; NERVE TISSUE PROTEINS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN AGGREGATES; PROTEOLYSIS; SUBSTRATE SPECIFICITY;

EID: 84915745964     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0111277     Document Type: Article

References (36)

1. Boutell JM, Thomas P, Neal JW, Weston VJ, Duce J, et al. (1999) Aberrant interactions of transcriptional repressor proteins with the Huntington's disease gene product, huntingtin. Hum Mol Genet 8: 1647-1655.
2. Steffan JS, Kazantsev A, Spasic-Boskovic O, Greenwald M, Zhu YZ, et al. (2000) The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc Natl Acad Sci U S A 97: 6763-6768.
3. Shimohata T, Nakajima T, Yamada M, Uchida C, Onodera O, et al. (2000) Expanded polyglutamine stretches interact with TAFII130, interfering with CREB-dependent transcription. Nat Genet 26: 29-36.
4. Nucifora FC Jr., Sasaki M, Peters MF, Huang H, Cooper JK, et al. (2001) Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science 291: 2423-2428.
5. Sadri-Vakili G, Cha JH (2006) Mechanisms of disease: Histone modifications in Huntington's disease. Nat Clin Pract Neurol 2: 330-338.
6. Steffan JS, Bodai L, Pallos J, Poelman M, McCampbell A, et al. (2001) Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 413: 739-743.
7. Ferrante RJ, Kubilus JK, Lee J, Ryu H, Beesen A, et al. (2003) Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J Neurosci 23: 9418-9427.
8. Hockly E, Richon VM, Woodman B, Smith DL, Zhou X, et al. (2003) Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc Natl Acad Sci U S A 100: 2041-2046.
9. Gardian G, Browne SE, Choi DK, Klivenyi P, Gregorio J, et al. (2005) Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. J Biol Chem 280: 556-563.
10. Pallos J, Bodai L, Lukacsovich T, Purcell JM, Steffan JS, et al. (2008) Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease. Hum Mol Genet 17: 3767-3775.
11. Mielcarek M, Landles C, Weiss A, Bradaia A, Seredenina T, et al. (2013) HDAC4 reduction: a novel therapeutic strategy to target cytoplasmic huntingtin and ameliorate neurodegeneration. PLoS Biol 11: e1001717.
12. Iwata A, Riley BE, Johnston JA, Kopito RR (2005) HDAC6 and microtubules are required for autophagic degradation of aggregated huntingtin. J Biol Chem 280: 40282-40292.
13. Kazantsev AG, Thompson LM (2008) Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat Rev Drug Discov 7: 854-868.
14. Thomas EA, Coppola G, Desplats PA, Tang B, Soragni E, et al. (2008) The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice. Proc Natl Acad Sci U S A 105: 15564-15569.
15. Hathorn T, Snyder-Keller A, Messer A (2011) Nicotinamide improves motor deficits and upregulates PGC-1alpha and BDNF gene expression in a mouse model of Huntington's disease. Neurobiol Dis 41: 43-50.
16. Jia H, Pallos J, Jacques V, Lau A, Tang B, et al. (2012) Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamineelicited phenotypes in model systems of Huntington's disease. Neurobiol Dis 46: 351-361.
17. Benn CL, Butler R, Mariner L, Nixon J, Moffitt H, et al. (2009) Genetic knockdown of HDAC7 does not ameliorate disease pathogenesis in the R6/2 mouse model of Huntington's disease. PLoS One 4: e5747.
18. Bobrowska A, Paganetti P, Matthias P, Bates GP (2011) Hdac6 knock-out increases tubulin acetylation but does not modify disease progression in the R6/2 mouse model of Huntington's disease. PLoS One 6: e20696.
19. Moumne L, Campbell K, Howland D, Ouyang Y, Bates GP (2012) Genetic knock-down of HDAC3 does not modify disease-related phenotypes in a mouse model of Huntington's disease. PLoS One 7: e31080.
20. Katsuno M, Adachi H, Kume A, Li M, Nakagomi Y, et al. (2002) Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuron 35: 843-854.
21. Klement IA, Skinner PJ, Kaytor MD, Yi H, Hersch SM, et al. (1998) Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice. Cell 95: 41-53.
22. Iwata A, Christianson JC, Bucci M, Ellerby LM, Nukina N, et al. (2005) Increased susceptibility of cytoplasmic over nuclear polyglutamine aggregates to autophagic degradation. Proc Natl Acad Sci U S A 102: 13135-13140.
23. Iwata A, Nagashima Y, Matsumoto L, Suzuki T, Yamanaka T, et al. (2009) Intranuclear degradation of polyglutamine aggregates by the ubiquitinproteasome system. J Biol Chem 284: 9796-9803.
24. Suzuki T, Kasuya Y, Itoh Y, Ota Y, Zhan P, et al. (2013) Identification of highly selective and potent histone deacetylase 3 inhibitors using click chemistry-based combinatorial fragment assembly. PLoS One 8: e68669.
25. Bardai FH, Verma P, Smith C, Rawat V, Wang L, et al. (2013) Disassociation of histone deacetylase-3 from normal huntingtin underlies mutant huntingtin neurotoxicity. J Neurosci 33: 11833-11838.
26. Duncan CE, An MC, Papanikolaou T, Rugani C, Vitelli C, et al. (2013) Histone deacetylase-3 interacts with ataxin-7 and is altered in a spinocerebellar ataxia type 7 mouse model. Mol Neurodegener 8: 42.
27. Bardai FH, D'Mello SR (2011) Selective toxicity by HDAC3 in neurons: regulation by Akt and GSK3beta. J Neurosci 31: 1746-1751.
28. Broide RS, Redwine JM, Aftahi N, Young W, Bloom FE, et al. (2007) Distribution of histone deacetylases 1-11 in the rat brain. J Mol Neurosci 31: 47-58.
29. Alenghat T, Meyers K, Mullican SE, Leitner K, Adeniji-Adele A, et al. (2008) Nuclear receptor corepressor and histone deacetylase 3 govern circadian metabolic physiology. Nature 456: 997-1000.
30. Cho Y, Sloutsky R, Naegle KM, Cavalli V (2013) Injury-induced HDAC5 nuclear export is essential for axon regeneration. Cell 155: 894-908.
31. Yang WM, Tsai SC, Wen YD, Fejer G, Seto E (2002) Functional domains of histone deacetylase-3. J Biol Chem 277: 9447-9454.
32. Jia H, Kast RJ, Steffan JS, Thomas EA (2012) Selective histone deacetylase (HDAC) inhibition imparts beneficial effects in Huntington's disease mice: implications for the ubiquitin-proteasomal and autophagy systems. Hum Mol Genet 21: 5280-5293.
33. Jeong H, Then F, Melia TJ Jr., Mazzulli JR, Cui L, et al. (2009) Acetylation targets mutant huntingtin to autophagosomes for degradation. Cell 137: 60-72.
34. Bence NF, Sampat RM, Kopito RR (2001) Impairment of the ubiquitinproteasome system by protein aggregation. Science 292: 1552-1555.
35. Hipp MS, Patel CN, Bersuker K, Riley BE, Kaiser SE, et al. (2012) Indirect inhibition of 26S proteasome activity in a cellular model of Huntington's disease. J Cell Biol 196: 573-587.
36. Bennett EJ, Bence NF, Jayakumar R, Kopito RR (2005) Global impairment of the ubiquitin-proteasome system by nuclear or cytoplasmic protein aggregates precedes inclusion body formation. Mol Cell 17: 351-365.